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Abstract
Purpose: Genome-wide association studies (GWAS) have identified 6q25, which incorporates the oestrogen receptor a gene
(ESR1), as a quantitative trait locus for areal bone mineral density (BMDa) of the hip and lumbar spine. The aim of this study
was to determine the influence of this locus on other bone health outcomes; calcaneal ultrasound (QUS) parameters, radial
peripheral quantitative computed tomography (pQCT) parameters and markers of bone turnover in a population sample of
European men.
Methods: Eight single nucleotide polymorphisms (SNP) in the 6q25 locus were genotyped in men aged 40–79 years from 7
European countries, participating in the European Male Ageing Study (EMAS). The associations between SNPs and
measured bone parameters were tested under an additive genetic model adjusting for centre using linear regression.
Results: 2468 men, mean (SD) aged 59.9 (11.1) years had QUS measurements performed and bone turnover marker levels
measured. A subset of 628 men had DXA and pQCT measurements. Multiple independent SNPs showed significant
associations with BMD using all three measurement techniques. Most notably, rs1999805 was associated with a 0.10 SD
(95%CI 0.05, 0.16; p = 0.0001) lower estimated BMD at the calcaneus, a 0.14 SD (95%CI 0.05, 0.24; p = 0.004) lower total hip
BMDa, a 0.12 SD (95%CI 0.02, 0.23; p = 0.026) lower lumbar spine BMDa and a 0.18 SD (95%CI 0.06, 0.29; p = 0.003) lower
trabecular BMD at the distal radius for each copy of the minor allele. There was no association with serum levels of bone
turnover markers and a single SNP which was associated with cortical density was also associated with cortical BMC and
thickness.
Conclusions: Our data replicate previous associations found between SNPs in the 6q25 locus and BMDa at the hip and
extend these data to include associations with calcaneal ultrasound parameters and radial volumetric BMD.
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Introduction
Oestrogens have positive effects on the development and
maintenance of the skeleton. These effects include the regulation
of bone turnover, acquisition of peak bone mass and inhibition of
bone loss. The majority of previous work has focussed on
oestrogens and the female skeleton, but more recent evidence
suggests that oestrogens are also required for the maintenance of
bone health in men [1–9]. The effects are mediated through
binding to specific oestrogen receptors (ER), which belong to the
nuclear hormone receptor superfamily and are expressed in a
number of cell types including osteoblasts, osteoclasts and bone
marrow stromal cells [10,11]. Two functional oestrogen receptors
have been identified so far, ERa and ERb. ERa appears to be the
major receptor, having a prominent effect on bone metabolism
[12].
The human gene for ERa, ESR1, is located on chromosome
6q25. Three polymorphisms in ESR1 have been widely studied to
date; two restriction fragment length polymorphisms in intron 1,
rs9340799 (XbaI) and rs2234693 (PvuII), and the (TA)n variable
number tandem repeat in the promoter region of the gene. Several
previous studies have found associations between these polymor-
phisms and osteoporosis related phenotypes, but the results are
somewhat conflicting possibly due to small sample sizes, variation
in study design and differences between the populations studied
[12]. In a large-scale meta-analysis of over 18,000 subjects, an
association was observed between rs9340799 and fracture risk in
women that was independent of areal bone mineral density
(BMDa), however, there was no association between rs2234693 or
the TA repeat and fracture and none of the polymorphisms were
associated with BMDa [13].
In recent years, genome-wide association studies (GWAS) have
been utilised to try to elucidate genetic predictors of bone health
using a hypothesis-free approach. One of the first GWAS,
conducted by Styrkarsdottir et al [14], reported a strong
association between the 6q25 region and dual energy x-ray
absorptiometry [DXA] hip and lumbar spine (LS) BMDa, which
has subsequently been replicated in independent populations [15].
This locus includes the 59 end of ESR1 and a gene of unknown
function (C6orf97) and is independent (r2,0.1, HapMap CEPH) of
the aforementioned widely studied polymorphisms. In a recent
meta-analysis, which utilised data from five GWAS and included
over 19,000 subjects, the locus at 6q25 was one of the region’s
most strongly associated with LS and femoral neck (FN) BMDa
[16].
The majority of genetic association studies of bone health have
focused on post-menopausal women with many of the large
cohorts consisting of predominantly females, therefore the role of
the 6q25 locus in male populations is less well characterised.
Previous work has understandably focused on areal bone density
(measured by DXA) at the two most clinically relevant
osteoporotic sites (hip and spine). However, there are limitations
in the assessment of bone health using DXA, one of the most
important being that BMDa is influenced by structural and
geometric parameters such as perisosteal expansion, cortical
density, cortical thickness, and trabecular number and thickness
[17]. For example, it is thought that periosteal expansion reflects
skeletal growth whereas cortical density reflects bone remodeling
[18]. More recently, techniques such as peripheral quantitative
computed tomography (pQCT) have been developed to allow
assessment of the structural and geometric components of bone.
However the influence of the 6q25 locus on pQCT parameters is
not clear. Futhermore, the influence the locus may have on bone
remodeling as measured by serum markers of bone formation and
resorption has yet to be determined. These parameters may have
distinct genetic determinants, knowledge of which could further
our understanding of the biological mechanisms underlying bone
health. In addition, DXA is not always practical, particularly in
large scale multi-site research studies. Thus techniques such as
quantitative ultrasound (QUS), which prospective studies have
shown to predict osteoporotic fracture as well as DXA [19–22],
have been utilised to assess bone health. The influence the 6q25
locus has on QUS parameters is not known.
The European Male Ageing Study (EMAS) is a large multi-
centre population based study of ageing in middle aged and elderly
European men which collected an extensive range of clinical,
biochemical and other health information. We used data from
EMAS to determine if the associations previously observed
between SNPs in 6q25 and DXA BMDa at the hip and spine
could be replicated. We then examined if 6q25 was associated with
bone health as measured by QUS at the calcaneus, pQCT at the
radius and serum markers of bone turnover.
Methods
Ethics statement
Ethical approval for the study was obtained in accordance with
local institutional requirements in each centre: Florence (Ethical
Committee of the Azienda Ospedaliera Careggi & University of
Florence), Leuven (Commissie Medische Ethiek UZ Gasthuisberg
& KU Leuven), Lodz (Bioethical Committee of Medical University
of Lodz for Human Studies), Malmo¨ (Ethical Committee of
Lund University), Manchester (North West Multi Centre Ethical
Research Committee, University of Manchester & CMMCUH),
Santiago de Compostela (Comite´ E´tico de Investigacio´n Clı´nica de
Galicia & Universidad de Santiago de Compostela), Szeged
(Human Investigation Review Board, University of Szeged) and
Tartu (Ethical Committee, Medical University of Tartu). All
ESR1 (6q25) Locus and Bone Health in Men
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subjects provided written informed consent. Approval for the
genetic analysis described here was obtained for seven of the eight
centres. Therefore, analysis was restricted to subjects from these
seven centres (all centres except for Malmo¨, Sweden).
Subjects
The subjects included in this analysis were recruited for
participation in EMAS. Detailed methods have been described
previously [23]. Briefly, men were recruited from population based
sampling frames in 8 European centres: Florence (Italy), Leuven
(Belgium), Lodz (Poland), Malmo¨ (Sweden), Manchester (UK),
Santiago de Compostela (Spain), Szeged (Hungary), Tartu
(Estonia). Stratified random sampling was used with the aim of
recruiting equal numbers of men in each of four 10-year age
bands: 40–49 years, 50–59 years, 60–69 years, and 70 years and
over.
Blood sampling and DNA extraction
Fasting blood samples were collected before 10 a.m. and
maintained at 0 to 4uC during all stages of the separation
procedures. After allowing whole blood samples to clot for 1 hour,
they were centrifuged at 3000 rev/min. The aliquots of plasma
and buffy coat were stored at 280uC. DNA was extracted from
leukocytes using standard phenol-chloroform extraction and
stored at 280uC prior to further analysis. Serum was also
separated immediately after phlebotomy and stored at 280uC.
Each serum sample was assayed for oestradiol (E2) and sex-
hormone binding globulin (SHBG). SHBG was measured by
Modular E170 platform electrochemiluminescence immunoassay
(Roche Diagnostics, Mannheim, Germany) at a single laboratory
(General Laboratory, Azienda Ospedaliero-Universitaria Careggi,
Florence, Italy) as described previously [24]. E2 was measured
using gas chromatography-mass spectroscopy (GC-MS) [25]. Free
(non-SHBG-bound) E2 levels were derived using the total
hormone measurement and levels of SHBG and albumin using
mass action equations and association constants [26] [27].
SNP selection and genotyping
SNPs in the ESR1 locus (6q25) associated with LS and/or Hip
BMDa in the GWAS conducted by Styrkarsdottir et al (2008) were
selected for genotyping (for results in Styrkarsdottir et al (2008) see
Table S1). The selected SNPs and proxies (r2 = 1) were genotyped
using Sequenom MassARRAY technology in accordance with the
manufacturer’s instructions. Sample and assay quality control
thresholds were set to 90%. SNPs were tested for deviation from
Hardy-Weinberg Equilibrium (HWE) and excluded from the
analysis if p,0.05 in the total population. Linkage disequilibrium
was examined using Haploview [28].
Bone assessments
Quantitative ultrasound (QUS). Quantitative ultrasound
(QUS) of the calcaneus was performed using the Sahara Clinical
Sonometer (Hologic Inc, Bedford, MA, USA) using a standardized
protocol. Each centre used the same machine model, and each
calibrated daily with the physical phantom provided by the
manufacturer. Outputs included broadband ultrasound
attenuation (BUA), speed of sound (SOS) and a machine derived
parameter: calcaneal bone mineral density (eBMD) in g/cm2,
eBMD = 0.0025926(BUA+SOS)23.687. To establish the short-
term precision of the method in this population, duplicate
measurements were performed in 20 randomly selected cohort
members in one of the centres (Leuven, Belgium). The in vivo CVs
were 2.8%, 0.3%, 3.4% for BUA, SOS and eBMD respectively.
Dual-energy x-ray absorptiometry (DXA). Areal bone
mineral density (BMDa) scans were carried out in two centres
(Manchester and Leuven). Both sites used dual-energy x-ray
absorptiometry (DXA) QDR 4500A devices from the same
manufacturer (Hologic Inc, Bedford, MA, USA). BMDa was
measured at the lumbar spine (L1 to L4) and proximal femur (total
region). All scans and analysis were performed by trained and
certified DXA technicians. The CVs for LS and total hip BMDa
were 0.57% and 0.56% in Leuven, respectively, and the CVs for
both LS and total hip were 0.97% in Manchester.
Peripheral Quantitative Computed Tomography (pQC-
T). Pexripheral QCT was performed in the same two centres as
the DXA measurements. The non-dominant radius was measured
using an XCT-2000 scanner (Stratec, Pforzheim, Germany) in
each centre following the manufacturer’s standard quality
assurance procedures. Total and trabecular volumetric BMD
(vBMD) (mg/mm3), and bone cross-sectional area (mm2) were
measured at the distal radius (4%) (voxel size 0.4 mm). Cortical
vBMD (mg/mm3); total, cortical and medullary area (mm2);
cortical thickness (mm); and stress strain index (SSI) (mm3) were
measured at the midshaft radius (50%) (voxel size 0.6 mm).
The European Forearm Phantom (EFP) was measured for cross-
calibration between the two centres; 10 repeat measurements were
taken in slices 1–4. The differences were less than precision error
for total, trabecular and cortical vBMD, and cortical area;
therefore, no cross-calibration was performed between the two
centres. The short term precision of 2 repeat measurements with
repositioning were: total vBMD 2.1% and 1.3%; trabecular
vBMD 1.27% and 1.42%; cortical vBMD 0.77% and 0.71%; and
cortical area 2.4% and 1.3%; in Manchester (n = 22) and Leuven
(n = 40), respectively.
Bone turnover markers. To assess bone resorption, serum
beta C-terminal telopeptide cross-linked telopeptide (b-cTX) was
measured on the Elecsys 2010 automated analyzer (Roche
Diagnostics GmbH, Mannheim, Germany) using the ß-
Crosslaps/serum reagents [29]. This assay is specific for cross-
linked ß-isomerized type I collagen C-telopeptide fragments and
uses two monoclonal antibodies, each recognizing the Glu-Lys-
Ala-His-ßAsp-Gly-Gly-Arg peptide (Crosslaps antigen). The intra-
assay CV evaluated by repeated measurements of several serum
samples was ,5.0%. The detection limit was 10 pg/mL. To
evaluate bone formation, measurements of P1NP were performed
on the Elecsys 2010 with a 2-site assay using monoclonal
antibodies raised against intact human P1NP purified from
human amniotic fluid. This assay detects both intact mono- and
trimeric forms (total P1NP), as previously described [30]. The
inter-assay CV was ,3.0% and the lower detection limit ,5 ng/
mL.
Statistical analysis
Subjects who reported either themselves or their parents or
grandparents as being born outside Europe and North America,
were excluded from the analysis to eliminate subjects with
potential non-European ancestry. Subjects taking either anti-
osteoporotic drugs or corticosteroids were also excluded. The bone
measures; total hip and lumbar spine BMDa, calcaneal QUS, bone
turnover markers and radial pQCT parameters were standardised:
z = (x2m)/)/s where x = raw value of bone measure, m= mean of
bone measure and s= standard deviation of bone measure. Linear
regression was used to test for association between SNPs and these
standardised bone measures under an additive genetic model
adjusting for centre, height and weight. Results are reported as a
percentage change (b) in a standard deviation (SD) with 95%
confidence intervals (95%CI) for each copy of the minor allele.
ESR1 (6q25) Locus and Bone Health in Men
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Significant associations were tested for heterogeneity between
centres (using SNP*centre interactions) due to significant differ-
ences in bone measures and allele frequencies between centres.
Associations with a p-value of ,0.05 were considered statistically
significant. Where multiple SNPs were significantly associated with
a bone measure, conditional analysis was used to identify the SNPs
independently associated (p,0.05) with the outcome.
The combined effect of multiple SNPs associated with the same
bone measure was assessed by calculating a score for each subject
that represented the total number of low BMD risk alleles carried.
Linear regression adjusting for centre, height and weight was used
to determine the association between the number of risk alleles
(assuming linearity) and the bone measure. Results are reported as
a percentage change (b) in a SD (95%CI) of the bone measure per
one allele increase in the number of risk alleles.
SNPs were also tested for interaction under an additive model
with E2 and free E2 as a continuous variable on measures of bone
with which they were previously associated, adjusting for centre,
height and weight. The effects of E2 and free E2 on the measure of
bone by genotype (assuming linearity) and the interaction p-values
are reported. All analysis was conducted in Stata version 9.2.
Power
With 80% power and 5% type I error under an additive genetic
model, the study was powered to detect effect sizes of greater than
0.2 SD for a minor allele frequency (MAF) = 0.05 and 0.1 SD for
MAF = 0.5 for QUS BMD, bone turnover markers and E2. For
DXA and pQCT measures, the study was powered to detect effect
sizes greater than 0.36 SD for MAF = 0.05 and 0.16 SD for
MAF = 0.5. Power was calculated using Quanto version 1.2.3 [31].
Results
Genotyping
Eight SNPs from the study of Styrkarsdottir et al [14] were
selected for genotyping in 2652 men who consented to genetic
analysis and for whom ethical approval was obtained, of which 7
SNPs were successfully genotyped in 2584 (97%) subjects.
Genotype data for rs3757317 was used as a proxy (r2 = 1,
HapMap CEPH) for rs3734803. All SNPs had a genotyping
success rate of .97% and HWE p.0.05. The LD between the
SNPs in the EMAS population is shown in Figure 1.
Subjects
In total, 2584 subjects were successfully genotyped. Subjects
with non-European ancestry (n = 16) or using anti-osteoporotic
drugs (n = 22) or corticosteroids (n = 78) were subsequently
excluded resulting in 2468 subjects with a mean (SD) age of
59.9 (11.1) years from 7 centres with data on QUS, bone turnover
markers and E2. A subset of these subjects (n = 628) also had data
on DXA and pQCT measurements. The subject characteristics
are shown in Table 1.
The association between the ESR1 (6q25) locus and bone
health
Of the 8 SNPs tested, 5 were significantly associated with total
hip BMDa (Table 2). All five SNPs (rs3757317, rs4870044,
rs1038304, rs6929137 and rs1999805) showed a similar size of
effect; 0.12–0.15 SD lower total hip BMDa for each copy of the
minor allele. Two of these SNPs (rs1038304 and rs1999805) were
also associated with lower BMDa at the lumbar spine with the
other three SNPs showing a trend towards an association with
lower BMDa at the lumbar spine that did not reach statistical
significance. Three of these SNPs (rs4870044, rs1038304 and
rs1999805) were also associated with lower ultrasound parameters
at the calcaneus. The results were broadly similar for all QUS
parameters (BUA, SOS and eBMD, which are highly correlated
(Table S2), so the results presented here are for eBMD. The largest
effect observed was for rs1999805 which showed a 0.11 SD
(95%CI 0.05, 0.16) lower eBMD for each copy of the minor allele.
The association between SNPs in the ESR1 (6q25) locus and
bone health at the radius measured by pQCT is shown in Table 3.
At the midshaft radius, the largest effect observed was for
rs4870044 (one of the SNPs associated with lower total hip BMDa
and calcaneal eBMD) which showed a 0.19 SD (95%CI 0.07, 0.31)
lower cortical density for each copy of the minor allele. Another
SNP, rs9479055, (also associated with lower calcaneal eBMD) was
associated with lower cortical density [0.13 SD (95%CI 0.01,
0.24)]. At the distal radius, two SNPs were significantly associated
with trabecular density. Rs1999805 and rs1030304 were associ-
ated with a 0.18 SD (95%CI 0.06, 0.29) and a 0.14 SD (95%CI
0.03, 0.25) lower trabecular density for each copy of the minor
allele, respectively. Both of these SNPs were also associated with
lower total hip BMDa and calcaneal eBMD. There was an
association between a single SNP and geometric pQCT
parameters at the radius. rs9479055 was associated with a
decrease in cortical BMC [b=22.18 (95%CI 23.99, 20.36)
p = 0.019 per allele] and cortical thickness [b=20.05 (95%CI
20.10, 20.01) p = 0.031 per allele]. This SNP was also associated
with lower midshaft cortical density and there is moderate
correlation between cortical density, BMC and thickness,
r = 0.44–0.82 (Table S2) There was no association between any
of the SNPs and markers of bone turnover, P1NP and b-cTX.
There was no evidence of heterogeneity between centres for any of
the significant associations.
In the conditional analysis the three SNPs associated with
eBMD (rs4870044, rs1038304 and rs1999805), were shown to
be independent of one another. Two SNPs, rs1038304 and
rs1999805, were independently associated with total hip BMDa.
Figure 1. Linkage disequilibrium between genotyped ESR1
(6q25) SNPs. Pair-wise values of D9 (coloured; white = 0, red = 1) and r2
(numbered) between SNPs genotyped in ESR1 (6q25) are shown.
doi:10.1371/journal.pone.0022037.g001
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Neither rs1999805 or rs1038304, were significantly independently
associated with LS BMDa, however, the effect estimates remained
similar (0.09 to 0.10 SD decrease per allele) to the individual SNP
effects when combined in the same model. rs4870044 was
significantly independently associated with cortical density and
rs1999805 was significantly independently associated with trabec-
ular density.
To examine the potential combined effect of SNPs in ESR1
(6q25) on bone health, a score was calculated (0–10) for each subject
that represented the total number of risk alleles carried for the five
SNPs associated with lower total hip BMDa (rs1999805, rs1038304,
rs4870044, rs6929137 & rs3757317). Increasing number of risk
alleles was associated with a lower total hip BMDa [20.06 SD
(95%CI20.09,20.03) p = 0.0002 per allele carried]. This is shown
in figure 2 along with the distribution of risk allele carriage. Similar
results were observed between increasing number of risk alleles and
LS BMDa [20.09 SD (95%CI 20.16, 20.02) p = 0.01], calcaneal
eBMD [20.06 SD (95%CI 20.09, 20.04) p = 6.0561026],
trabecular [20.13 (95%CI 20.20, 20.05) p = 0.001] and cortical
density [20.09 SD (95%CI 20.16, 20.03) p = 0.005].
The association between total / free E2 and bone density
by ESR1 (6q25) genotypes
As expected, increasing levels of both total and free E2 (pmol/l)
were associated with higher BMDa (expressed as SDs) at the hip
(Total E2: b= 0.003 SDs per pmol/l; 95%CI = 0.0002, 0.006, Free
E2: b= 0.32; 95%CI = 0.14, 0.50) and spine (Total E2: b= 0.005
SDs per pmol/l; 95%CI = 0.002, 0.008, Free E2: b= 0.36;
95%CI = 0.18, 0.53). Free E2 was also associated with higher
QUS calcaneal eBMD (b= 0.33 ; 95%CI = 0.24, 0.42) and
trabecular density (b= 0.23 ; 95%CI = 0.04, 0.42) at the radius
as previously reported [9,32] but did not reach a significant
association with cortical density (b= 0.18 ; 95%CI =20.01, 0.37)
at the radius. None of the 8 SNPs were associated with either total
or free E2 levels, however, when the positive association between
total E2 and total hip BMDa was stratified by the number of risk
alleles of rs1038304, the strongest increase was observed in those
with no risk alleles (b= 0.010; 95%CI = 0.003, 0.014), a smaller
increase was observed in those with 1 risk allele (b= 0.002;
95%CI =20.0005, 0.005) and there was no association in those
with two risk alleles (b=20.004; 95%CI =20.008, 0.001). This
interaction was statistically significant (p = 0.006). A similar
interaction was observed between rs1038304 and E2 on LS
BMDa.(p = 0.025).
An interaction effect was also observed when the association
between free E2 and total hip BMDa was stratified by rs1038304
(p = 0.007) (Table 4). Interaction effects werealso observed when
the associations between free E2 and LS BMDa and radius
trabecular density were stratified by rs1038304 alleles, Table 4.
Table 1. Subject Characteristics.
Variable Mean (SD)
Age at interview (years) 59.9 (11.1)
Total oestradiol (pmol/L) 74.0 (25.1)
Free oestradiol (pmol/L) 1.25 (0.43)
QUS
Broadband attentuation (dB/MHz) 80.2 (19.1)
Speed of sound (m/s) 1551 (34.5)
Calcaneal eBMD (g/cm2) 0.54 (0.14)
Bone turnover
b-cTX (ng/ml) 43.1 (21.5)
P1NP (ng/ml) 359.9 (181.9)
DXA
Lumbar spine BMDa (g/cm
2) 1.06 (0.18)
Total hip BMDa (g/cm
2) 1.01 (0.14)
pQCT
Cortical density (mg/cm3) 1155.9 (38.2)
Cortical BMC (mg/mm) 122.3 (17.2)
Total area (mm2) 149.6 (21.7)
Cortical thickness (mm) 3.24 (0.43)
Medullary area (mm2) 43.2 (17.6)
Cross-sectional muscle area (mm2) 3658.1 (632.9)
Stress strain index (mm3) 337.34 (64.84)
Total density (mg/cm3) 399.4 (72.3)
Total area (mm2) 375.8 (67.18)
Trabecular density (mg/cm3) 203.51 (43.2)
doi:10.1371/journal.pone.0022037.t001
Table 2. Association between the ESR1 (6q25) locus and QUS eBMD and DXA BMDa.
SNP Chr position Base change MAF Total hip BMDa Lumbar spine BMDa Calcaneal eBMD
b (95%CI) p-value b (95%CI p-value b (95%CI
p-
value
rs9479055 151889660 ARC 0.41 20.03 (20.13, 0.07) 0.565 20.01 (20.12, 0.10) 0.848 20.05 (20.10, 0.01) 0.080
rs4463269 151903921 CRT 0.30 20.00 (20.11, 0.11) 0.957 20.01 (20.13, 0.11) 0.829 20.01 (20.07, 0.05) 0.637
rs3757317 151907224 CRT 0.15 20.14 (20.27, 20.01) 0.036 20.09 (20.23, 0.05) 0.221 20.06 (20.13, 0.02) 0.140
rs4869738 151933844 GRT 0.24 0.01 (20.11, 0.12) 0.935 20.02 (20.15, 0.10) 0.714 20.03 (20.09, 0.04) 0.405
rs4870044 151943102 CRT 0.28 20.12 (20.23, 20.02) 0.021 20.05 (20.17, 0.06) 0.371 20.10 (20.15, 20.04) 0.002
rs1038304 151974868 ARG 0.49 20.15 (20.25, 20.05) 0.003 20.11 (20.22, 20.003) 0.045 20.08 (20.13, 20.02) 0.004
rs6929137 151978370 GRA 0.31 20.13 (20.24, 20.03) 0.013 20.08 (20.20, 0.03) 0.152 20.05 (20.11, 0.01) 0.131
rs1999805 152110057 TRC 0.41 20.14 (20.24, 20.05) 0.004 20.12 (20.23, 20.02) 0.026 20.11 (20.16, 20.05) 0.0001
b, effect estimates are shown as standardized values (standard deviations above or below the population average) for each copy of the minor allele adjusted for height
and weight.
doi:10.1371/journal.pone.0022037.t002
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Discussion
Here we report, in a population sample of European Caucasian
men, significant association between SNPs in the ESR1 (6q25)
locus and bone phenotypes at different anatomical sites using a
variety of densitometric techniques. We confirm the findings of a
previous GWAS, showing a significant association between this
locus and total hip and lumbar spine BMDa with very similar
magnitude of effect (0.1 SD per copy of minor allele, Table S1). In
addition, we observed association between several of the SNPs and
calcaneal ultrasound eBMD of similar magnitude to that of BMDa.
We also observed associations with cortical and trabecular density
at the radius. Only 2 of the 8 SNPs were associated with lumbar
spine BMDa but others showed an effect in the same direction but
just failed to attain statistical significance which may be due to the
relatively small sample size compared to the GWAS or possibly
technical artefact as BMDa of the spine can be artificially raised in
an elderly population by concomitant degenerative disc disease
and osteoarthritis, potentially disguising any real influence these
SNPs may have on bone density.
To our knowledge this is the first study to examine the influence
of the ESR1 (6q25) locus on calcaneal QUS parameters. We found
associations between the SNPs and higher QUS parameters, of
similar magnitude to that of total hip BMDa. We previously
investigated four other SNPs in ESR1 (rs488133, rs2077647,
rs1801132 and rs726282) for an association with calcaneal QUS
parameters. These showed only very modest evidence of
association in heterozygous individuals only [33]. However, there
is no LD between these four SNPs and the SNPs investigated in
this analysis. The associations reported here are much stronger
and taken with the previously reported associations with BMDa at
the genome-wide significance level, suggests that the 6q25 locus is
an important locus in determining bone health.
In our study, we observed that rs9479055 and rs4870044 were
associated with higher cortical density, and rs1038304 and
rs1999805 were associated with higher trabecular density at the
Table 3. Association between the ESR1 (6q25) locus and pQCT BMD.
SNP Chr position Base change MAF Midshaft radius cortical density Distal radius trabecular density
b (95%CI) p-value b (95%CI) p-value
rs9479055 151889660 ARC 0.41 20.13 (20.24, 20.01) 0.028 20.07 (20.19, 0.05) 0.266
rs4463269 151903921 CRT 0.30 20.04 (20.16, 0.09) 0.531 20.01 (20.14, 0.12) 0.890
rs3757317 151907224 CRT 0.15 20.12 (20.27, 0.03) 0.119 20.05 (20.21, 0.11) 0.562
rs4869738 151933844 GRT 0.24 20.01 (20.14, 0.13) 0.917 0.01 (20.13, 0.15) 0.881
rs4870044 151943102 CRT 0.28 20.19 (20.31, 20.07) 0.002 20.12 (20.24, 0.01) 0.065
rs1038304 151974868 ARG 0.49 20.03 (20.14, 0.08) 0.604 20.14 (20.25, 20.03) 0.016
rs6929137 151978370 GRA 0.31 20.01 (20.13, 0.11) 0.842 20.08 (20.20, 0.04) 0.206
rs1999805 152110057 TRC 0.41 20.08 (20.19, 0.03) 0.148 20.18 (20.29, 20.06) 0.003
b, effect estimates are shown as standardized values (standard deviations above or below the population average) for each copy of the minor allele adjusted for height
and weight.
doi:10.1371/journal.pone.0022037.t003
Figure 2. The association between the number of risk alleles and total hip BMDa. Histogram and line plot showing the combined effect of
alleles associated with lower total hip BMDa. The line represents the standardised mean (SD) for total hip BMDa by the number of low total hip BMDa
risk alleles. The dashed lines are the upper and lower bounds of the 95% confidence intervals of the mean.
doi:10.1371/journal.pone.0022037.g002
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radius. Few studies have examined the influence of this genetic
locus on volumetric bone density or bone geometry. A study of
3113 boys and girls from the Avon Longitudinal Study of Parents
and Children (ALSPAC) found that rs1038304 was associated with
cortical BMD at the tibia [34]. This study did not examine any of
the other ESR1 (6q25) SNPs or the trabecular compartment of the
tibia. ALSPAC found no association with any of the geometric
parameters [34], in keeping with our findings and tending to
suggest that the effect of 6q25 on BMD is not via an influence on
skeletal size.
While our data replicate previous associations found between
SNPs in the 6q25 locus and BMDa at the hip and extend these
data to include associations with calcaneal ultrasound parameters
and radial volumetric BMD, we observed no associations with the
markers of bone turnover P1NP and b-cTX. In older men,
increased bone turnover markers have been shown to be
associated with lower BMDa and, more recently, poor bone
microarchitecture [35,36]. In line with these cross-sectional
findings, prospective data have confirmed that higher levels of
bone remodeling may be associated with increased rates of bone
loss, although evidence for an increased risk of fracture is lacking
[37–39]. Our results suggest that the effect on bone health of the
individual SNPs studied in this analysis was independent of an
effect on bone remodeling. To our knowledge, no other studies
have examined this relationship. Previous studies have investigated
other regions of ESR1 and bone turnover but have produced
conflicting results [12].The reasons for this remain to be clarified.
Examining our results overall, three SNPs in particular were
consistently associated with bone health. Rs1038304 and
rs1999805 were associated with higher hip BMDa, calcaneal
QUS and trabecular density at the distal radius. Rs4870044 was
associated with higher hip BMDa, calcaneal QUS and cortical
density at the mid-shaft radius. These three SNPs span a 220 kb
region, with rs1038304 and rs4870044 being located in intronic
regions of C6orf97 (a gene of unknown function upstream of ESR1)
and rs1999805 is located within intron 2 of a splice variant of
ESR1. We showed that these three SNPs were independently
associated with eBMD, the BMD measure for which the largest
sample size was available. For the other BMD measures these
SNPs were not always significantly independent, however, the
effect estimates remained similar suggesting that the lack of ability
to identify independent associations was due to the reduced sample
size for the DXA and pQCT measures of BMD. In addition, LD
between these SNPs is low and Stykarsdottir et al. [14] also
observed that independent associations with bone density exist at
this locus. Recent studies have also identified significant differences
between European and East Asian populations at this locus for
DXA BMD with large differences in allele frequencies observed
for many SNPs [40,41]. Furthermore, these SNPs are not in LD
with the three most widely studied polymorphisms in ESR1,
namely rs2234693, rs9340799 and the (TA)n variable number
tandem repeat [12], indicating that the pattern of association
across ESR1 is complex. The fact that we observed associations
across a number of anatomical sites irrespective of the densito-
metric technique used provides further evidence that 6q25 is an
important genetic determinant of bone health.
Interestingly, we observed that the expected positive relation-
ship between serum levels of total / free E2 and hip BMDa and our
previously reported association between free E2 and distal radius
trabecular density [32] were moderated by rs1038304. A weak
interaction was also seen with rs6929137. This suggests that these
SNPs may influence the ability of ESR1 to mediate the action of
oestradiol. These interactions, however, require replication in
independent populations to determine if this is a true effect.
EMAS is a large, multi-centre population based study using
standardised methods to assess both genetic variation and related
phenotypes. However, there are a number of limitations that need
to be considered when interpreting the results. The overall
response rate for participation was 45%, and it is possible that
those invited but declined to participate may have differed from
those who agreed to participate. Caution is required therefore in
interpreting absolute values; both the frequency of individual SNPs
and the phenotype data. However, given that the main analysis
was based on an internal comparison of the participants, it is
unlikely that any selection factors would have influenced the main
findings. In any multi-centre study, there is the possibility of
population stratification. In our study there was no evidence of any
between centre heterogeneity and the likelihood of population
stratification was minimised by excluding subjects of non-
European ancestry. False-negative results may have occurred
owing to power constraints, particularly in relation to the findings
for DXA and pQCT. False positive associations might have
occurred due to multiple testing as only a single association
(rs1999805 and calcaneal eBMD) reached a bonferroni corrected
p-value threshold of 0.00037, however, this threshold does not
account for the correlation between bone measures (Table S2).
However, the number of SNPs examined was relatively small and
these SNPs have been shown to be associated with BMDa at the
genome-wide significance level in previous studies.
We observed the effect of each individual SNP on bone health
to be modest. This is in keeping with the majority of studies
examining the contribution of genetic factors to bone health.
Individual SNPs may not be useful in predicting individuals at
risk of developing osteoporosis. However, it remains possible
these risk markers may contribute to a genetic risk profile that in
combination with environmental predictors might help identify
at-risk individuals. Analysing the combined effects of the
associated SNPs in the locus showed that compared to subjects
Table 4. Association between free E2 and bone density by ESR1 (6q25) genotypes.
Outcome SNP N copies of allele p-value
0 1 2
b (95%CI) b (95%CI) b (95%CI)
Total hip BMDa rs1038304 0.50 (0.19, 0.82) 0.17 (0.002, 0.34) 20.17 (20.44, 0.11) 0.007
Lumbar spine BMDa rs1038304 0.58 (0.23, 0.93) 0.23 (0.05, 0.41) 20.12 (20.42, 0.18) 0.011
Trabecular density rs1038304 0.54 (0.17, 0.91) 0.25 (0.05, 0.45) 20.04 (20.37, 0.28) 0.046
b, effect estimates are shown as standardized values (standard deviations) per pmol/L change in free E2; p-value is for the interaction.
doi:10.1371/journal.pone.0022037.t004
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with no risk alleles, those with all the risk alleles had a
considerably lower BMD. This suggests that the additive effect
of SNPs in this locus may have a large impact on BMD in a small
number of individuals. However, limiting the analysis to those
SNPs associated with BMD may have introduced bias. We also
analysed the combined effect of all SNPs genotyped on each of
the BMD measures (data not shown). Except for LS BMDa, the
effect was significant for all BMD measures. The effect sizes,
however, were much smaller e.g. for total hip BMDa the
combined effect of all SNPs tested (per allele) was half of the
combined effect of the SNPs associated with total hip BMDa.
Further work is required to identify the full complement of
genetic predictors of bone health and how they interact with each
other and non-genetic risk factors.
In conclusion, our data replicate previous associations found
between SNPs in the ESR1 (6q25) locus and BMDa at the hip and
extend these data to include associations with calcaneal ultrasound
parameters and radial volumetric BMD. If these findings are
confirmed in other independent populations, fine mapping and
functional studies may lead to identification of causal variants and
their modes of action. The significance of these findings in relation
to male osteoporosis also merits further study.
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